Industry stakeholders have moved beyond considering patients as clinical trial “subjects”, and instead recognise the tremendous value of viewing those most impacted by a disease as partners
The detrimental issues within health systems in developing countries have become intrinsic to their model, with lack of funding and resources, as well as systemic issues, causing inequality
Recently, pharmaphorum spoke with Sebastian Katz, chief strategy officer of specialty healthcare company Stein Holding Group (SteinCares), to discuss the announcement of its licensing agree
